| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2013PLoSO...854506Y |
| P356 | DOI | 10.1371/JOURNAL.PONE.0054506 |
| P932 | PMC publication ID | 3551754 |
| P698 | PubMed publication ID | 23349911 |
| P5875 | ResearchGate publication ID | 235372268 |
| P50 | author | Akseli Hemminki | Q26920981 |
| Markus Vähä-Koskela | Q42305481 | ||
| Johanna Arola | Q96050653 | ||
| Kalle Saksela | Q30158253 | ||
| P2093 | author name string | Heikki Mäkisalo | |
| Erkko Ylösmäki | |||
| Sari Jäämaa | |||
| Sergio Lavilla-Alonso | |||
| Taija af Hällström | |||
| P2860 | cites work | MicroRNAs: target recognition and regulatory functions | Q24609584 |
| Downregulation of miR-122 in the rodent and human hepatocellular carcinomas | Q24631076 | ||
| A mammalian microRNA expression atlas based on small RNA library sequencing | Q24644709 | ||
| miRBase: tools for microRNA genomics | Q24649872 | ||
| MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib | Q24655048 | ||
| Harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines | Q37019252 | ||
| The roles of microRNAs in mammalian virus infection | Q37094312 | ||
| Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer | Q37291653 | ||
| Armed replicating adenoviruses for cancer virotherapy | Q37386616 | ||
| Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis | Q37460094 | ||
| Antiviral effects of human microRNAs and conservation of their target sites | Q37904339 | ||
| Oncolytic virotherapy | Q38025263 | ||
| Infection of Mouse Liver by Human Adenovirus Type 5 | Q40171854 | ||
| A custom microarray platform for analysis of microRNA gene expression | Q40443862 | ||
| Tumor measurement in the nude mouse | Q41355093 | ||
| H-ras gene is expressed at the G1 phase in primary cultures of hepatocytes | Q43908749 | ||
| Adenovirus E1A under the control of heterologous promoters: wide variation in E1A expression levels has little effect on virus replication | Q44367401 | ||
| Adenovirus serotype 5 hexon mediates liver gene transfer | Q45875068 | ||
| CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors | Q45880041 | ||
| Liver-directed gene transfer in non-human primates | Q45882569 | ||
| Determination of subcutaneous tumor size in athymic (nude) mice | Q46296687 | ||
| A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. | Q52537791 | ||
| Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer | Q53863989 | ||
| Growth factor dependence of progression through G1 and S phases of adult rat hepatocytes in vitro. Evidence of a mitogen restriction point in mid-late G1 | Q71070506 | ||
| Comparison of five incubation systems for rat liver slices using functional and viability parameters | Q73951905 | ||
| Organ slices as an in vitro test system for drug metabolism in human liver, lung and kidney | Q84589627 | ||
| Identification of tissue-specific microRNAs from mouse | Q27860892 | ||
| MicroRNA signatures in human cancers | Q27860962 | ||
| MicroRNAs: genomics, biogenesis, mechanism, and function | Q27861070 | ||
| Characterization of microRNA expression profiles in normal human tissues | Q29615492 | ||
| Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection | Q29615959 | ||
| Growth of human hepatoma cells lines with differentiated functions in chemically defined medium | Q29617962 | ||
| E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors | Q31934618 | ||
| Use of tissue-specific microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cells | Q33450551 | ||
| Double-detargeted oncolytic adenovirus shows replication arrest in liver cells and retains neuroendocrine cell killing ability | Q33527419 | ||
| MicroRNAs and the regulation of vector tropism | Q33713311 | ||
| Current issues and future directions of oncolytic adenoviruses | Q33730705 | ||
| Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data | Q33761673 | ||
| Replication-selective adenoviruses as oncolytic agents | Q33882702 | ||
| The Rb/E2F pathway: expanding roles and emerging paradigms | Q34052659 | ||
| Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus | Q34469114 | ||
| MicroRNA controlled adenovirus mediates anti-cancer efficacy without affecting endogenous microRNA activity | Q34478419 | ||
| Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species | Q34545667 | ||
| miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. | Q34592976 | ||
| Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA. | Q34830129 | ||
| Engineering microRNA responsiveness to decrease virus pathogenicity | Q34866393 | ||
| MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma | Q34964774 | ||
| Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties | Q34993023 | ||
| Viruses and microRNAs: RISCy interactions with serious consequences | Q35263282 | ||
| Roles for microRNAs in conferring robustness to biological processes | Q35955737 | ||
| Current advances and future challenges in Adenoviral vector biology and targeting | Q36463004 | ||
| Unique MicroRNA signature and clinical outcome of cancers | Q36822466 | ||
| miRNA profiling for diagnosis and prognosis of human cancer | Q36822471 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | microRNA | Q310899 |
| Adenoviridae | Q193447 | ||
| oncolytic virus | Q1560099 | ||
| P304 | page(s) | e54506 | |
| P577 | publication date | 2013-01-22 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | MicroRNA-mediated suppression of oncolytic adenovirus replication in human liver | |
| P478 | volume | 8 |
| Q27307206 | Anti-tumor activity of a miR-199-dependent oncolytic adenovirus |
| Q35532741 | Dual miRNA targeting restricts host range and attenuates neurovirulence of flaviviruses |
| Q39429511 | Impact of Autophagy in Oncolytic Adenoviral Therapy for Cancer |
| Q35742497 | Late-phase miRNA-controlled oncolytic adenovirus for selective killing of cancer cells. |
| Q28601803 | MicroRNA-Detargeted Mengovirus for Oncolytic Virotherapy |
| Q38964020 | MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus. |
| Q26745822 | MicroRNA-regulated viral vectors for gene therapy |
| Q34675280 | MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches. |
| Q24567699 | New viruses for cancer therapy: meeting clinical needs |
| Q38842126 | Oncolytic virotherapy for urological cancers |
| Q37346014 | RNA viruses and microRNAs: challenging discoveries for the 21st century. |
| Q27014034 | Role of microRNAs in hepatocellular carcinoma: a clinical perspective |
| Q63880718 | Targeting macrophage- and intestinal epithelial cell-specific microRNAs against norovirus restricts replication in vivo. |
| Q28072347 | Trial Watch-Oncolytic viruses and cancer therapy |
| Q27021951 | Trial Watch:: Oncolytic viruses for cancer therapy |
| Q34422828 | miR-148a- and miR-216a-regulated oncolytic adenoviruses targeting pancreatic tumors attenuate tissue damage without perturbation of miRNA activity |
Search more.